PubMed Health⌕ Search

Biomedical subjects

E Glass

Publications and source records attributed to E Glass.

27 records · Page 2Linked to original sources
PubMed1982

Development of a transplantable model of pancreatic duct adenocarcinoma.

We report here the first development of a continuous cell line in tissue culture of an animal pancreatic duct adenocarcinoma that is histologically similar to human pancreatic duct adenocarcinoma. A primary pancreatic duct adenocarcinoma, induced in a male Syrian golden hamster after 23 weeks of weekly subcutaneous injection of N-nitrobis (2-hydroxypropyl)amine, was minced and injected subcutaneously into three hamsters. After 8 weeks, a single tumor was apparent. Subsequent passages of fragments into the cheek pouches were performed at 3- to 4-week intervals. After five passages, minced fragments of a tumor were placed in tissue culture. Colonies appeared by 7 days; an epitheloid cell line, without fibroblasts, was established by 60 days. Single-cell suspensions, injected into hamster cheek pouches or subcutaneously, produced tumors in a dose-dependent fashion. Spent culture medium of tissue culture cells and saline extracts of freshly excised tumors contained pancreatic oncofetal antigen-like activity.

Adenocarcinoma↗
PubMed1981

Presence of bacterial binding 'lectin-like' receptors on phagocytes.

Lectin-like receptors capable of binding the bacterium Staphylococcus albus have been demonstrated in the membranes of phagocytes including macrophages, neutrophils and eosinophils from various sources and species. Such receptors are likely to contribute to bacterial adherence and phagocytosis in the non-immune animal.

Animals↗
PubMedDate not supplied

Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma.

BACKGROUND: Lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection (LM/SL/SCLND) is an increasingly popular alternative to elective lymphadenectomy (ELND) for patients with early-stage melanoma. Although several reports have demonstrated the accuracy of the LM/SL technique, there are no data on its therapeutic value. METHODS: We performed a matched-pair statistical analysis of 534 patients with clinical stage I melanoma; one half of the patients were treated with LM/SL and the other half were treated with ELND. Patients in the two treatment groups were matched for age (54% were < or =50 years of age), gender (63% were male patients), site of the primary melanoma (49% were on the extremities, 36% on the trunk, and 15% on the head and neck), and thickness of the primary melanoma (7% were < 0.75 mm, 42% between 0.75 and 1.5 mm, 43% between 1.51 and 4.0 mm, and 8% > 4 mm). Patients in the LM/SL group underwent complete regional lymphadenectomy (SCLND) only if the LM/SL specimen contained metastatic melanoma. RESULTS: The overall incidences of nodal metastases were no different (P = .18) between LM/SL (15.7%) and ELND (12%) groups, but the incidence of occult nodal disease was significantly (P = .025) higher among patients with intermediate-thickness (1.51-4.0-mm) primary tumors who underwent LM/SL (23.7%) instead of ELND (12.2%). Survival data were compared by the log-rank score test. LM/SL/SCLND and ELND resulted in equivalent 5-year rates of disease-free survival (79 +/- 3.3% and 84 +/- 2.2%, respectively; P = .25) and overall survival (88 +/- 3.0% and 86 +/- 2.1%, respectively; P = .98). The LM/SL and ELND groups also exhibited similar incidences of same-basin recurrences (4.8% vs. 2.1%, P = .10, respectively) and in-transit metastases (2.6% vs. 3.8%, P = .48) after tumor-negative dissections. Patients who underwent ELND showed a higher incidence of distant recurrences (8.9% vs. 4.0%, P = .03), but this may be related to the longer follow-up period for these patients (median, 169 months), compared with the LM/SL-treated patients (45 months). Among patients with tumor-positive nodal dissections, the 5-year overall survival rates were higher, and approached significance (P = .077) for patients treated by LM/SL/SCLND (64 +/- 12%) compared with ELND (45 +/- 10%). CONCLUSIONS: These findings suggest that LM/SL/SCLND is therapeutically equivalent to ELND but may be more effective for identifying nodal metastases in patients with intermediate-thickness primary tumors.

Biopsy↗
PubMedDate not supplied

Motor neuron abiotrophy in a saluki.

A nine-week-old saluki puppy was presented to Tufts University School of Veterinary Medicine for progressive, generalized weakness and bilateral forelimb deformities. Examination suggested a diffuse neuromuscular lesion. Cerebrospinal fluid (CSF) analysis showed normal nucleated cell count and protein level; however, many macrophages had vacuolated cytoplasm. Electromyography (EMG) recordings suggested denervation in paraspinal and appendicular muscles. Tibial motor nerve conduction velocity was normal, but direct evoked muscle potential had reduced amplitude. Histopathology revealed diffuse, symmetrical, degenerative motor neuronopathy of the ventral horn of the spinal cord with associated lesions in nerves and muscles. Histopathology was consistent with an abiotrophy that was likely inherited.

Animals↗
PubMedDate not supplied

Response to xenograft technology: a new frontier in medicine. Xenograft technology: proceed with caution.

Many Americans do not deal well with aging or preparing for death as a natural part of life. One indication of this is that only about 15% of the population have completed advance directives. Growing old gracefully and dying with dignity are not foremost considerations in our culture. We ask our government and private industry to spend billions of health care dollars to prolong our lives at all costs. Organ xenotransplantation has the potential of being a very complex, high tech, and expensive way of saving lives from the jaws of death--for a few more months or years. Derenge and Bartucci (1999) pointedly ask, "...should we instead be providing support and comfort to those who are dying and not intervene?" (p. 432). Finally, Dr. Margaret Somerville from the McGill Centre of Medicine, Ethics, and Law reminds us of the importance of addressing ethical issues early during the research process. Somerville (1998) states, "It is not enough to do ethics as an add-on at the end of having done your science." Science, medicine, and ethics, in the case of xenotransplantation, must progress together. Leaders in social policy should address the issues presented here before xenotransplantation is undertaken in the United States.

Animals↗
PubMedDate not supplied

Ethical issues in oncology nursing practice: an overview of topics and strategies.

An understanding of common principles of biomedical ethics provide healthcare professions with a common language. Developing a standard approach to complex ethical cases in clinical situations allows professionals to involve significant individuals and to ensure that appropriate factors are considered. This article presents a case in oncology nursing practice, using a sample model for decision making. The case is developed to demonstrate a number of issues that arise with regard to symptom management, the nurse-patient relationship, informed consent, end-of-life decisions, and truth-telling. Ethical dilemmas arising from conflicts within principles and between individuals holding differing ethical perspectives are described. Because a true ethical dilemma goes beyond a simple "right" or "wrong" answer, arguments based on differing moral grounds are presented. Nursing responsibilities are delineated and directions are provided for furthering one's understanding of ethics.

Advance Directives↗